Achilles Therapeutics Targets The Root Of Cancer
Executive Summary
Emerging Company Profile: With funding from Cancer Research UK and Syncona – and a wealth of science from its founders – newly launched London-based immuno-oncology company Achilles Therapeutics, believes it has identified cancer's weak spot.
You may also be interested in...
Achilles On Getting ‘New Wave’ Immunotherapy From Concept To Clinic In Three Years
Clonal neoantigen immunotherapy developer Achilles Therapeutics tells the Pink Sheet how the regulatory landscape for advanced therapies might not be as tricky as it used to be.
Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus
ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.
A Supercharged Charitable Investment Fund To Nurture UK's Biotech Ecosystem
The UK’s largest medical charities, the Wellcome Trust and Cancer Research UK, have backed the formation of a bulked-up £1bn long-term investment fund from the bringing together of Syncona, the CRT Pioneer Fund and BACIT, with the aim of building a self-sustaining UK biotech ecosystem.